These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 35784280)

  • 1. Review: Sustainable Clinical Development of CAR-T Cells - Switching From Viral Transduction Towards CRISPR-Cas Gene Editing.
    Wagner DL; Koehl U; Chmielewski M; Scheid C; Stripecke R
    Front Immunol; 2022; 13():865424. PubMed ID: 35784280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
    Dimitri A; Herbst F; Fraietta JA
    Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells.
    Glaser V; Flugel C; Kath J; Du W; Drosdek V; Franke C; Stein M; Pruß A; Schmueck-Henneresse M; Volk HD; Reinke P; Wagner DL
    Genome Biol; 2023 Apr; 24(1):89. PubMed ID: 37095570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells.
    Kath J; Franke C; Drosdek V; Du W; Glaser V; Fuster-Garcia C; Stein M; Zittel T; Schulenberg S; Porter CE; Andersch L; Künkele A; Alcaniz J; Hoffmann J; Abken H; Abou-El-Enein M; Pruß A; Suzuki M; Cathomen T; Stripecke R; Volk HD; Reinke P; Schmueck-Henneresse M; Wagner DL
    Blood; 2024 Jun; 143(25):2599-2611. PubMed ID: 38493479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering strategies to safely drive CAR T-cells into the future.
    Rossi M; Breman E
    Front Immunol; 2024; 15():1411393. PubMed ID: 38962002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.
    Maganti HB; Kirkham AM; Bailey AJM; Shorr R; Kekre N; Pineault N; Allan DS
    Cytotherapy; 2022 Apr; 24(4):405-412. PubMed ID: 35039239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
    Liu J; Zhou G; Zhang L; Zhao Q
    Front Immunol; 2019; 10():456. PubMed ID: 30941126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
    Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
    Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
    Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.
    Salas-Mckee J; Kong W; Gladney WL; Jadlowsky JK; Plesa G; Davis MM; Fraietta JA
    Hum Vaccin Immunother; 2019; 15(5):1126-1132. PubMed ID: 30735463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
    Huang D; Miller M; Ashok B; Jain S; Peppas NA
    Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
    Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
    Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow.
    Yu T; Jhita N; Shankles P; Fedanov A; Kramer N; Raikar SS; Sulchek T
    Lab Chip; 2023 Nov; 23(22):4804-4820. PubMed ID: 37830228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR-T cell therapy.
    Ding R; Chao CC; Gao Q
    Methods Cell Biol; 2022; 167():1-14. PubMed ID: 35152989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies.
    Jung IY; Lee J
    Mol Cells; 2018 Aug; 41(8):717-723. PubMed ID: 30110720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells.
    Sterner RM; Cox MJ; Sakemura R; Kenderian SS
    J Vis Exp; 2019 Jul; (149):. PubMed ID: 31380838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy.
    Wellhausen N; Agarwal S; Rommel PC; Gill SI; June CH
    Curr Opin Immunol; 2022 Feb; 74():76-84. PubMed ID: 34798542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
    Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
    Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.